DionyMed Brands to buy Los Angeles Cannabis Operations for $19 Million

Visit the Dionymed Brands Investor Dashboard and stay up to date with data-driven, fact based due diligence for active traders and investors.

DionyMed Brands Inc. Signs Binding Term Sheet to Acquire 1.83 Acre Southern California Cannabis Campus from MMAC

DionyMed Strengthens Distribution and Direct-to-Consumer Platform in the Los Angeles Market

TORONTO–(BUSINESS WIRE)–DionyMed Brands Inc. (“DionyMed” or “Company”) (CSE: DYME), a multi-state cannabis brands platform, announced today it has signed a binding term sheet with MM Esperanza 2 LLC, doing business as “MMAC,” to acquire select MMAC assets (the “Acquisition”), including the 1.83 acre Los Angeles cannabis campus that includes a dispensary storefront, distribution facility, manufacturing hub and direct-to-consumer fulfillment center. The acquisition includes all property, leaseholds, equipment and licenses for a purchase price of USD$19,000,000 and enhances DionyMed’s brands distribution and direct-to-consumer footprint in Southern California.

Completion of this arms-length acquisition is subject to several conditions, including, but not limited to, the execution and delivery of definitive documentation mutually agreeable to the parties, completion of due diligence on MMAC to the Company’s sole satisfaction and receipt of all board, shareholder, regulatory and third-party approvals for the Acquisition.

Located in the heart of Los Angeles, MMAC’s 1.83 acre campus serves the Southern California cannabis market with a well-established retail storefront, a distribution, manufacturing, and direct-to-consumer fulfillment center supporting all of Los Angeles County. Under the terms of the agreement, DionyMed will pay MMAC USD$13,000,000 in cash, subject to financing, and USD$6,000,000 in DionyMed Common Shares.

ulfillment center supporting all of Los Angeles County. Under the terms of the agreement, DionyMed will pay MMAC $13,000,000 in cash and $6,000,000 in DionyMed Common Shares.

This acquisition accelerates the DYME brands portfolio in the world’s largest cannabis market – California. Together, with our existing Northern California footprint, this market leading cannabis campus supports our vision for bringing safe, trusted cannabis brands to consumers throughout the entire state.

Edward Fields, CEO of DionyMed

Cameron Smith, COO of MMAC, commented, “Now that we’ve established our Los Angeles platform, the sale of the property provides MMAC additional working capital to quickly expand its footprint beyond the Los Angeles area. Further, by partnering with DionyMed, one of the top operators in the cannabis industry, we can utilize their efficient direct-to-consumer cannabis platform to drive increased awareness of our brands.”

To be added to the DionyMed e-mail distribution list, please e-mail DionyMed@kcsa.com with DionyMed in the subject line.

About DionyMed
Founded in 2017, DionyMed is a multi-state cannabis brands, distribution and delivery platform, supporting cultivators, manufacturers and award-winning brands in the medical and adult-use cannabis markets. DionyMed sells branded products in every category from flower to vape cartridges, concentrates and edibles. DionyMed serves more than 700 dispensaries and completes over 40,000 Direct-To-Consumer deliveries each month with its growing portfolio of products and brands. Learn more at www.DionyMed.com and follow @DYME_Inc on Twitter and LinkedIn.

Original press release

For fact-based information on Dionymed Brands, view the company’s sponsored Investor Dashboard.

Get ahead of the crowd by signing up for 420 Investor, the largest & most comprehensive premium subscription service for cannabis traders and investors since 2013.

Published by NCV Newswire
NCV Newswire
The NCV Newswire by New Cannabis Ventures aims to curate high quality content and information about leading cannabis companies to help our readers filter out the noise and to stay on top of the most important cannabis business news. The NCV Newswire is hand-curated by an editor and not automated in anyway. Have a confidential news tip? Get in touch.

Get Our Sunday Newsletter